Article

Combined Menin and XPO1 inhibition drive synergistic antileukemic activity in <i>KMT2A</i> r and <i>NPM1</i> -m AML

2026-03-13

Abstract excerpt

Menin scaffolds the oncogenic histone-lysine-N-methyltransferase (KMT2A)-fusion protein (FP) complex in KMT2A- r and wild-type KMT2A complex in NPM1 -m acute myeloid leukemia (AML). Menin inhibitors (MIs) are effective in KMT2A -r AML and NPM1 -m AML. However, not all patients respond to MIs as monotherapy. In this preclinical study, we demonstrate that the MI ziftomenib, in combination with the XPO1 inhibito...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 1204a898-eaa2-5924-a05f-ae216ca75891
DOI: 10.64898/2026.03.10.710924

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Combined Menin and XPO1 inhibition drive synergistic antileukemic activity in <i>KMT2A</i> r and <i>NPM1</i> -m AMLDOI 10.64898/2026.03.10.710924Read

Targeting the Menin-KMT2A Axis in Acute Leukemia: From Epigenetic Dependency to Clinical Translation.Semantic proximity Read

Menin inhibitors in the treatment of acute myeloid leukemiaSemantic proximity Read

Menin Inhibitors in Acute Myeloid Leukemia-What Does the Future Hold?Semantic proximity Read

Menin Inhibitors: A New Era of Targeted Therapies in Acute Myeloid Leukemia.Semantic proximity Read

Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c).Semantic proximity Read

Combination Strategies with Menin Inhibitors for Acute LeukemiaSemantic proximity Read

Small Molecule Menin Inhibitors: Novel Therapeutic Agents Targeting Acute Myeloid Leukemia with KMT2A Rearrangement or NPM1 MutationSemantic proximity Read

Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1Semantic proximity Read

Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1Semantic proximity Read

Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemiasSemantic proximity Read

Menin inhibitors in KMT2A-rearranged and NPM1-mutated acute leukemia: A scoping review of safety and efficacySemantic proximity Read

Targeting chromatin modifying complexes in acute myeloid leukemiaSemantic proximity Read